Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCB-2019 Vaccine Immunogenicity and Safety in Chinese Adults
NCT04954131Phase 2Unknown
- Sponsor
- Clover Biopharmaceuticals
- Start
- Aug 2021
- Primary completion
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing SCB-2019 with Placebo (2 arms). Primary endpoint: Geometric Mean Titer ratio of GMT-CLO-SCB-2019-010 over GMT-CLO-SCB-2019-003 at Day 36. Status: unknown.
02
Drugs
SCB-2019
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04954131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04954131.